JHSPH NCRC Profile picture
Led by @JohnsHopkinsSPH faculty, the Novel #Coronavirus Research Compendium rapidly reviews literature. Sign up for our weekly newsletter https://t.co/jYbm3MUl4P
25 Aug
We reviewed the first analysis of mortality among patients receiving #ConvalescentPlasma therapy from #COVID19 survivors through the US Expanded Access Program. The effect of #ConvalescentPlasma on #COVID19 mortality has not previously been well described bit.ly/3gpFGDn
In full disclosure, the lead author is based at Hopkins; however, none of the NCRC reviewers were direct collaborators. Thus, the article had an independent external review by someone without current or past professional collaborations with the author and no Hopkins affiliation.
In this preprint on @medrxivpreprint, Joyner et al analyzed 35,322 hospitalized #COVID19 patients from 1,809 sites overseen by @MayoClinic, from April 4-July 4. They assessed if timing of #ConvalescentPlasma reduced #mortality and if higher doses of #antibodies reduced mortality.
Read 9 tweets
5 May
What evidence has the @JHSPH_NCRC reviewed to date on treatments for COVID-19? 💊💉🩸
From Gautret et al. in International Journal of Antimicrobial Agents:
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov
From Gautret et al. in International Journal of Antimicrobial Agents:
The study did not formally assess clinical endpoints, and it is unclear whether there is #COVID19 clinical benefit with #hydroxychloroquine treatment. bit.ly/2W5meov
Read 8 tweets